For patients with JAK2V617F mutation-positive ET and PV, there were no significant differences in the overall response rate between the groups treated with IFN-α or HU (P > 0.05); however, the patients treated with IFN-α had a significantly higher 5-year PFS than those treated with HU (P < 0.05) (Table 2). The gene discussed is IFNA1; the disease is acquired polycythemia vera.